
C4 Imaging

C4 Imaging develops medical devices that enable clinical teams to more accurately perform image-guided procedures. The company’s proprietary technology, C4, has been developed as Sirius®, a positive-signal MRI marker designed to improve quality assessment after prostate cancer treatment with brachytherapy, as well as Orion™, an MRI marker that enables accurate MRI–based pre-treatment planning for cancer patients being treated with high dose rate (HDR) brachytherapy.
C4 Imaging’s multimodality non-metallic fiducial marker, Nova™, will be launched in 2021; Nova™ will allow the benefits of positive-signal MRI treatment management to be offered to patients receiving radiotherapy and proton therapy.
Nova: A New Non-metallic Multimodality Fiducial Marker
Sirius - post implant seed localization
Orion: Positive MRI signal HDR planning line marker
Resources
-
OrionPositive signal MRI line marker for HDR brachytherapy planningYou must log in to access content.
Contact Information
C4 Imaging
6575 West Loop South, Suite 500
Bellaire, TX 77401
609 933 5895
Jesse Nieto (jnieto@c4imaging.com)
Andrew Bright (abright@c4imaging.com)
Chat with Us
Chat room questions will be answered by a C4 Imaging representative.
Access Date | Quiz Result | Score | Actions |
---|
Registrant Login
Need Tech Support?
If you are using Internet Explorer this site will not function properly for you - please switch to another browser such as Google Chrome, Mozilla Firefox, Safari, etc.
Need further support? Please visit our FAQs page.